The immune systems of most cancer patients make antibodies that selectively recognize the tumor yet ultimately fail to kill tumor cells. Dr. Meyer’s lab will develop new ways of measuring how these antibodies interact with the immune system and test the hypothesis that they fail to function due to blocked or counterproductive interactions due to variation in their Fc domains.
Dr. Meyer received his BS from the University of California, Los Angeles, and his PhD from the Massachusetts Institute of Technology, followed by an independent fellowship at the Koch Institute for Integrative Cancer Research. In 2017, he joined the Bioengineering Department at the University of California, Los Angeles, where he uses proteomics and computational models to measure, model, and therapeutically manipulate cell-to-cell communication.